United States Biotechnology & Medical Research

Protagenic Therapeutics Inc (PTIX)

Track

Protagenic Therapeutics Inc. witnessed two recent open-market purchases by Executive Chair Garo H. Armen. These acquisitions, totaling approximately 6,100 USD, occurred during a period where the stock price declined by 61.5% over ninety days. No other insider activity was recorded, and the company has not released a recent earnings report.
Ticker: PTIX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Buy 5 Aug 2026
Value US$1,515,293.34 | Price 448.41 | Shares 28,606 (-15.3%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-06 2026-08-05 B Purchase
2.4
ARMEN GARO H

EXEC. CHAIR & PRINCIPAL OFF

Executive Director
28,606 -15.3%
448.41
US$1,515,293 		28,606 -15.3% 448.41 US$1,515,293
2026-08-03 2026-07-30 B Purchase
2.4
ARMEN GARO H

EXEC. CHAIR & PRINCIPAL OFF.

Executive Director
5,485 +9.2%
19.77
US$164,145 		5,485 +9.2% 19.77 US$164,145
2023-10-13 2023-10-12 B Purchase
Arrow Alexander K.

Chief Financial Officer

Officer
40,714 +4.0%
395.64
US$1,307,666 		40,714 +4.0% 395.64 US$1,307,666
2022-05-18 2022-05-18 B Purchase
Arrow Alexander K.

Chief Financial Officer

Officer
8,000 +5.6%
0.72
US$5,760 		8,000 +5.6% 0.72 US$5,760
2022-05-18 2022-05-17 B Purchase
Arrow Alexander K.

Chief Financial Officer

Officer
23,000 +19.1%
0.71
US$16,330 		23,000 +19.1% 0.71 US$16,330
2021-05-03 2021-04-30 B Purchase
Arrow Alexander K.

Chief Financial Officer

Officer
1,000 +0.8%
2.29
US$2,290 		1,000 +0.8% 2.29 US$2,290
2021-05-03 2021-04-29 B Purchase
Arrow Alexander K.

Chief Financial Officer

Officer
1,000 +0.8%
2.29
US$2,290 		1,000 +0.8% 2.29 US$2,290
2016-08-18 2016-06-17 B Purchase ARMEN GARO H

See Remarks

Executive Director Large shareholder
60,211 +1.4%
1.25
US$75,264 		60,211 +1.4% 1.25 US$75,264
2010-12-15 2010-12-13 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
1,758 +0.4%
2.09
US$3,674 		1,758 +0.4% 2.09 US$3,674
2010-12-15 2010-12-13 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
300 +0.1%
2.08
US$624 		300 +0.1% 2.08 US$624
2010-12-15 2010-12-13 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
569 +0.1%
2.07
US$1,178 		569 +0.1% 2.07 US$1,178
2010-12-15 2010-12-13 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
74 +0.0%
2.00
US$148 		74 +0.0% 2.00 US$148
2010-12-15 2010-12-13 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
1,334 +0.3%
1.99
US$2,655 		1,334 +0.3% 1.99 US$2,655
2010-12-15 2010-12-13 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
900 +0.2%
1.98
US$1,782 		900 +0.2% 1.98 US$1,782
2010-12-15 2010-12-13 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
266 +0.1%
1.97
US$524 		266 +0.1% 1.97 US$524
2010-12-15 2010-12-10 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
5,000 +1.1%
1.90
US$9,500 		5,000 +1.1% 1.90 US$9,500
2010-12-15 2010-12-10 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
3,499 +0.8%
1.79
US$6,263 		3,499 +0.8% 1.79 US$6,263
2010-12-15 2010-12-10 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
100 +0.0%
1.70
US$170 		100 +0.0% 1.70 US$170
2010-12-15 2010-12-10 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
100 +0.0%
1.64
US$164 		100 +0.0% 1.64 US$164
2010-12-15 2010-12-10 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
600 +0.1%
1.63
US$978 		600 +0.1% 1.63 US$978
2010-12-15 2010-12-10 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
300 +0.1%
1.60
US$480 		300 +0.1% 1.60 US$480
2010-12-15 2010-12-10 B Purchase MUSCI RAYMOND

Exec VP, Corporate Development

Executive Director
200 +0.0%
1.59
US$318 		200 +0.0% 1.59 US$318
2010-01-07 2009-12-21 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
5,376 +0.2%
0.60
US$3,226 		5,376 +0.2% 0.60 US$3,226
2010-01-07 2009-12-14 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
527,683 +20.4%
0.65
US$342,888 		527,683 +20.4% 0.65 US$342,888
2010-01-07 2009-12-09 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
21,947 +0.9%
0.67
US$14,704 		21,947 +0.9% 0.67 US$14,704
2010-01-07 2009-12-08 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
86,386 +3.5%
0.66
US$56,989 		86,386 +3.5% 0.66 US$56,989
2010-01-07 2009-11-19 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
25,000 +1.0%
0.85
US$21,250 		25,000 +1.0% 0.85 US$21,250
2010-01-07 2009-11-16 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
50,500 +2.1%
0.85
US$42,925 		50,500 +2.1% 0.85 US$42,925
2010-01-07 2009-11-13 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
50,000 +2.1%
0.86
US$42,920 		50,000 +2.1% 0.86 US$42,920
2010-01-07 2009-11-12 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
11,100 +0.5%
0.85
US$9,435 		11,100 +0.5% 0.85 US$9,435
2008-11-26 2008-11-25 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
25,000 +1.1%
1.17
US$29,290 		25,000 +1.1% 1.17 US$29,290
2008-09-03 2008-08-29 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
25,000 +1.1%
4.03
US$100,655 		25,000 +1.1% 4.03 US$100,655
2008-06-17 2008-06-13 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
10,000 +0.4%
4.30
US$42,968 		10,000 +0.4% 4.30 US$42,968
2008-06-12 2008-06-11 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
10,000 +0.4%
4.36
US$43,601 		10,000 +0.4% 4.36 US$43,601
2008-06-12 2008-06-10 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
10,000 +0.4%
4.31
US$43,107 		10,000 +0.4% 4.31 US$43,107
2008-06-09 2008-06-05 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
10,000 +0.4%
4.21
US$42,071 		10,000 +0.4% 4.21 US$42,071
2008-06-02 2008-06-02 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
35,000 +1.6%
4.00
US$140,000 		35,000 +1.6% 4.00 US$140,000
2008-06-02 2008-05-30 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
35,000 +1.6%
4.56
US$159,750 		35,000 +1.6% 4.56 US$159,750
2007-12-03 2007-11-30 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
12,500 +0.8%
14.00
US$175,000 		12,500 +0.8% 14.00 US$175,000
2007-03-06 2007-02-12 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
360,000,000 +516.1%
0.01
US$3,492,000 		360,000,000 +516.1% 0.01 US$3,492,000
2007-03-06 2007-02-12 B Purchase Trinad Capital Master Fund Ltd. Large shareholder
360,000,000 +516.1%
0.01
US$3,492,000 		360,000,000 +516.1% 0.01 US$3,492,000
2006-10-27 2006-10-24 S Sale Banon Sid

Former Director
586,222 -90.8%
0.02
US$11,724 		586,222 -90.8% 0.02 US$11,724
2006-10-27 2006-10-24 S Sale CHAZEN JEROME A Non-Executive Director
2,344,887 -90.8%
0.02
US$46,898 		2,344,887 -90.8% 0.02 US$46,898
2006-10-26 2006-10-24 S Sale KIER ISAAC Non-Executive Director
17,586,652 -90.8%
0.02
US$351,733 		17,586,652 -90.8% 0.02 US$351,733
Explore more

More insider trading research around Protagenic Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America